Overview

A Study in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System

Status:
Not yet recruiting

Trial end date:
2024-10-01

Target enrollment:

Participant gender:

Summary

This is a single center Phase I/II study to determine the safety of the administration of mutation reactive autologous lymphocytes with knockout of the CISH gene in adults with metastatic gastrointestinal epithelial cancer that have failed prior therapy. Up to 5 dose levels of cytokine-induced SH2 protein (CISH) inactivated tumor infiltrating lymphocytes (TILs) will be tested during a Phase I dose escalation plan followed by a Phase II Simon two-stage design portion.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Treatments:

Aldesleukin